SCHEMBL5457285

SCHEMBL5457285

OC1CCN(Cc2ccc(CCCNc3ccc(-c4ccc(Cl)cc4)cn3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 10/20 0.54
HTR2A P28223 6/20 0.54
CHRM1 P11229 4/20 0.54
F10 P00742 1/20 0.48
PDCD1 Q15116 2/20 0.46
CD274 Q9NZQ7 2/20 0.46
CHEK1 O14757 1/20 0.45
ACHE P22303 1/20 0.45
CYP2D6 P10635 2/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
LSS P48449 1/20 0.41
ENPP2 Q13822 2/20 0.40
DRD2 P14416 1/20 0.40
ADRA1A P35348 1/20 0.40
DRD3 P35462 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5440352 0.85 MCHR1 (0.54) MCHR1HTR2ACHRM1PDCD1CD274
SCHEMBL5433383 0.80 MCHR1 (0.53) MCHR1HTR2ACHRM1CYP2D6LSS
SCHEMBL14504828 0.80 MCHR1 (0.53) MCHR1HTR2ACHRM1PDCD1CD274
SCHEMBL4592745 0.80 MCHR1 (0.43) MCHR1HTR2ACHRM1ALDH1A1RAB9A
SCHEMBL4141085 0.74 ALDH1A1 (0.60) ACHECYP2D6MEN1ALDH1A1RAB9A
SCHEMBL5426586 0.73 MCHR1 (0.74) MCHR1HTR2ACHRM1ACHECYP2D6
SCHEMBL9491586 0.72 ESR1 (0.47) CYP2D6ALDH1A1RAB9A
SCHEMBL3858059 0.69 MCHR1 (0.59) MCHR1HTR2ACHRM1F10PDCD1
SCHEMBL447773 0.68 MCHR1 (0.59) MCHR1HTR2ACHRM1ACHECYP2D6
SCHEMBL24008985 0.67 RAB9A (0.64) ACHECYP2D6MEN1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds ROTH GERALD J 2007-05-17 US disclosed
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds ROTH GERALD J 2007-05-17 US disclosed
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds ROTH GERALD J 2007-05-17 US disclosed
WO-2007048802-A1 (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 MCHR1 1/4885HTR2A 66/4885CHRM1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.